Findings from a new clinical appraisal of molecular profiling for clinical decision making in advanced cancer.
Exclusive partner of Caris Molecular Intelligence in Australia and New Zealand. 
Clinical papers
Dean A, Byrne A, Marinova M, Hayden I. Clinical outcomes of patients with rare and heavily pretreated solid tumours treated according to the results of tumour molecular profiling. Biomed Res Int. 2016;2016:4627214.
Patients with rare and heavily pretreated solid tumours show significant clinical benefit after Caris Molecular Intelligence-guided treatment.
Herzog TJ, Spetzler D, Xiao N, et al. Impact of molecular profiling on overall survival of patients with advanced ovarian cancer. Oncotarget. 2016; 7: 19840-19849.
Improvement in overall survival for patients with advanced ovarian cancer treated matching Caris Molecular Intelligence profiling recommendations.
Janssens J, Gallagher WM, Dean A, Ussia G, Stamp G. Tumor profiling-directed precision cancer therapy – comparison of commercial and academic clinical utility. Int J Surg Surgical Proced. 2017; 2: 123.
Comparison of four commercially available tumour profiling services highlights superiority of Caris Molecular Intelligence.
Purim O, Beny A, Inbar M, et al. Biomarker-driven therapy in metastatic gastric and esophageal cancer: Real-life clinical experience. Target Oncol. 2018 Apr;13(2):217-226.
Caris’s biomarker driven therapy demonstrates clinical benefit for nearly 30% of patients with difficult-to-treat metastatic gastric and oesophageal cancer.
Spetzler D, Xiao N, Burnett K, et al. Multi-platform molecular profiling of 1,180 patients increase median overall survival and influences treatment decision in 53% of cases. Eur J Cancer. 2015; 51(Suppl 3):S44.
Multi-platform molecular profiling increases the median overall survival of those who receive treatment with clinical benefit by 422 days from time of profiling.
Ussia G, Leonard R, Janssens J. Multi-platform tumour profiling delivers the highest clinical utility and improves patient outcomes in today’s routine clinical practice. Int J Surg Surgical Proced. 2016; 1:107.
Caris Molecular Intelligence has the highest clinical utility and is improving patient outcomes in clinical practice.
Vanderwalde A, Spetzler D, Xiao N, et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018;7(3):746-756.
Study demonstrates Next-Generation Sequencing can determine microsatellite instability status among cancer types, identifies subset of patients who may benefit from immunotherapy.
Von Hoff DD, Stephenson JJ Jr, Rosen P, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010; 28(33):4877-83.
Pilot study shows applicability of Caris Molecular Intelligence to improve patient outcomes in clinical practice.
Created: February 20, 2018 - Modified: June 28, 2019